Key points are not available for this paper at this time.
Continuing five or more locoregional therapies for recurrent HCC after LR is related to poor recurrence-free survival after SLT.
Rhu et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: